Genetic Interaction between Tau and the Apolipoprotein e Receptor LRP1 Increases Alzheimer's Disease Risk

Dementia and Geriatric Cognitive Disorders

Volumn 28, Issue 2, 2009, Pages 116-120

  Vázquez Higuera, José Luis ^a   Mateo, Ignacio ^a   Sánchez Juan, Pascual ^a   Rodríguez Rodríguez, Eloy ^a   Pozueta, Ana ^a   Infante, Jon ^a   Berciano, José ^a   Combarros, Onofre ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Alzheimer's disease; Cholesterol; Genetic polymorphism; Low density lipoprotein receptor related protein 1 (LRP1); Tau phosphorylation

Indexed keywords

APOLIPOPROTEIN E; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; TAU PROTEIN;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE INTERACTION; GENOTYPE; GROUPS BY AGE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK; SEX DIFFERENCE;

AGED; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; FEMALE; HUMANS; LDL-RECEPTOR RELATED PROTEIN 1; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; RISK; SPAIN; TAU PROTEINS;

EID: 68549085398     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000234913     Document Type: Article

References (24)

1. Ballatore C, Lee VMY, Trojanowski JQ: Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007; 8: 663-672.
2. Distl R, Meske V, Ohm TG: Tangle-bearing neurons contain more free cholesterol than adjacent tangle-free neurons. Acta Neuropathol 2001; 101: 547-554.
3. Bu G: Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 2009; 10: 333-344.
4. Ohm TG, Scharnagl H, März W, Bohl J: Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions. Acta Neuropathol 1999; 98: 273-280.
5. Tesseur I, Van Dorpe J, Spittaels K, Van den Haute C, Moechars D, Van Leuven F: Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am J Pathol 2000; 156: 951-964.
6. Distl R, Treiber-Held S, Albert F, Meske V, Harzer K, Ohm TG: Cholesterol storage and tau pathology in Niemann-Pick type C disease in the brain. J Pathol 2003; 200: 104-111.
7. Vance JE, Hayashi H, Karten B: Cholesterol homeostasis in neurons and glial cells. Semin Cell Dev Biol 2005; 16: 193-212.
8. Sánchez-Guerra M, Combarros O, Infante J, Llorca J, Berciano J, Fontalba A, Fernández-Luna JL, Pena N, Fernández-Viadero C: Case-control study and meta-analysis of low density lipoprotein receptor-related protein gene exon 3 polymorphism in Alzheimer's disease. Neurosci Lett 2001; 316: 17-20.
9. Pritchard A, Harris J, Pritchard CW, St Clair D, Lemmon H, Lambert JC, Chartier-Harlin MC, Hayes A, Thaker U, Iwatsubo T, Mann DMA, Lendon C: Association study and meta-analysis of low-density lipoprotein receptor related protein in Alzheimer's disease. Neurosci Lett 2005; 382: 221-226.
10. Myers AJ, Kaleem M, Marlowe L, Pittman AM, Lees AJ, Fung HC, Duckworth J, Leung D, Gibson A, Morris CM, de Silva R, Hardy J: The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. Hum Mol Genet 2005; 14: 2399-2404.
11. McKhaan G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 934-944.
12. Donahue JE, Flaherty SL, Johanson CE, Duncan III JA, Silverberg GD, Miller MC, Tavares R, Yang W, Wu Q, Sabo E, Hovanesian V, Stopa EG: RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 2006; 112: 405-415.
13. Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, Wagner SL, Troncoso JC, Kawas CH, Katzman R, Koo EH: Modulation of amyloid f -protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 2000; 106: 1159-1166.
14. Herz J: The LDL receptor gene family: (un)expected signal transducers in the brain. Neuron 2001; 29: 571-581. (Pubitemid 32323932)
15. Reddy JV, Ganley IG, Pfeffer SR: Clues to neuro-degeneration in Niemann-Pick type C disease from global gene expression profiling. PLoS ONE 2006; 1:e19.
16. Combarros O, Cortina-Borja M, Smith AD, Lehmann DJ: Epistasis in sporadic Alzheimer's disease. Neurobiol Aging 2009; 30: 1333-1349.
17. McKeith IG, Perry RH, Morris CM, Trojanowski JQ, Clark C, Karlawish J, Arnold S, Forman MS, Van Deerlin V, de Silva R, Hardy J: The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis 2007; 25: 561-570.
18. Puglielli L, Tanzi RE, Kovacs DM: Alzheimer's disease: the cholesterol connection. Nat Neurosci 2003; 6: 345-351.
19. Haag MDM, Hofman A, Koudstaal PJ, Stricker BHC, Breteler MMB: Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam study. J Neurol Neurosurg Psychiatry 2009; 80: 13-17.
20. Sparks L, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, Wasser D, Johnson-Traver S, Lochhead J, Ziolwolski C: Atorvastatin for the treatment of mild to moderate Alzheimer disease. Arch Neurol 2005; 62: 753-757.
21. Masse I, Bordet R, Deplanque D, Al Khedr A, Richard F, Libersa C, Pasquier F: Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005; 76: 1624-1629.
22. Li G, Larson EB , Sonnen JA, Shofer JB, Petrie EC, Schantz A, Peskind ER, Raskind MA, Breitner JCS, Montine TJ: Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 2007; 69: 878-885.
23. Boimel M, Grigoriadis N, Lourbopoulos A, Touloumi O, Rosenmann D, Abramsky O, Rosenmann H: Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. J Neuropathol Exp Neurol 2009; 68: 314-325.
24. Solomon A, Kivipelto M: Cholesterol-modifying strategies for Alzheimer's disease. Expert Rev Neurother 2009; 9: 695-709.